Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth

Blood

Volumn 94, Issue 7, 1999, Pages 2461-2468

  Pike, Sandra E ^b   Yao, Lei ^b   Setsuda, Joyce ^b   Jones, Karen D ^b   Cherney, Barry ^b   Appella, Ettore ^b   Sakaguchi, Kazuyasu ^b   Nakhasi, Hira ^b   Atreya, Chintamani D ^b   Teruya Feldstein, Julie ^b   Wirth, Peter ^b   Gupta, Ghanshyam ^b   Tosato, Giovanna ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CALRETICULIN; GLUTATHIONE TRANSFERASE; MALTOSE BINDING PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASOSTATIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CATTLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; HEART; IMMUNOHISTOCHEMISTRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; TUMOR BLOOD FLOW;

EID: 0033214331     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2461.419a26_2461_2468     Document Type: Article

References (41)

1. Folkman J: Angiogenesis: Initiation and control. Ann NY Acad Sci 401:212, 1982
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353, 1996
3. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624, 1990
4. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555, 1990
5. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292, 1993
6. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841, 1993
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082, 1994
8. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157, 1994
9. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79:315, 1994
10. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12 [see comments]. J Natl Cancer Inst 87:581, 1995
11. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G: Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791, 1996
12. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 89:2635, 1997
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277, 1997
14. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222, 1997
15. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 84:6471, 1987
16. Roberts DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 10:1183, 1996
17. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390:404, 1997
18. Kerbel RS: A cancer therapy resistant to resistance [news; comment] [see comments]. Nature 390:335, 1997
19. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287, 1998
20. Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G: Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188:1, 1998
21. Homandberg GA, Williams JE, Grant D, Schumacher B, Eisenstein R: Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. Am J Pathol 120:327, 1985
22. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwati S, Kleinman HK, Reaman GH, Tosato G: Human Interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155, 1995
23. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 67:519, 1992
24. Singh NK, Atreya CD, Nakhasi HL: Identification of calreticulin as a rubella virus RNA binding protein. Proc Natl Acad Sci USA 91:12770, 1994
25. Atreya CD, Singh NK, Nakhasi HL: The rubella virus RNA binding activity of human calreticulin is localized to the N-terminal domain. J Virol 69:3848, 1995
26. Li G, Waltham M, Anderson NL, Unsworth E, Treston A, Weinstein IN: Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Electrophoresis 18:391, 1997
27. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, Cox AL, Appella E, Engelhard VH: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry [see comments]. Science 255:1261, 1992
28. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G: Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93:1612, 1999
29. Nash PD, Opas M, Michalak M: Calreticulin: Not just another calcium-binding protein. Mol Cell Biochem 135:71, 1994
30. Krause KH, Michalak M: Calreticulin. Cell 88:439, 1997
31. Burns K, Michalak M: Interactions of calreticulin with proteins of the endoplasmic and sarcoplasmic reticulum membranes. FEBS Lett 318:181, 1993
32. Kuwabara K, Pinsky DJ, Schmidt AM, Benedict C, Brett J, Ogawa S, Broekman MJ, Marcus AJ, Sciacca RR, Michalak M, Wang F, Pan YC, Grunfeld S, Patton S, Malinski T, Stern DM, Ryan J: Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries. J Biol Chem 270:8179, 1995
33. Hawn TR, Tom TD, Strand M: Molecular cloning and expression of Sm1rV1, a Schistosoma mansoni antigen with similarity to calnexin, calreticulin, and OvRa11. J Biol Chem 268:7692, 1993
34. Dedhar S, Rennie PS, Shago M, Hagesteijn CYL, Yang H, Filmus J, Hawley RG, Bruchovsky N, Cheng H, Matusik RJ, Giguère V: Inhibition of nuclear hormone receptor activity by calreticulin. Nature 367:480, 1994
35. Coppolino MG, Woodside MJ, Demaurex N, Grinstein S, St-Arnaud R, Dedhar S: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature 386:843, 1997
36. Burns K, Duggan B, Atkinson EA, Famulski KS, Nemer M, Bleackley RC, Michalak M: Modulation of gene expression by calreticulin binding to the glucocorticoid receptor. Nature 367:476, 1994
37. Kishore U, Sontheimer RD, Sastry KN, Zaner KS, Zappi EG, Hughes GR, Khamashta MA, Strong P, Reid KB, Eggleton P: Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J 322:543, 1997
38. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122:497, 1993
39. Pipili-Synetos E, Sakkoula E, Haralabopoulos G, Andriopoulou P, Peristeris P, Maragoudakis ME: Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 111:894, 1994
40. Lau YT, Ma WC: Nitric oxide inhibits migration of cultured endothelial cells. Biochem Biophys Res Commun 221:670, 1996
41. Hanahan D: A flanking attack on cancer [news]. Nat Med 4:13, 1998